Siemens Health/€SHL
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Siemens Health
Siemens Healthineers AG, listed under the ticker SHL, operates in the healthcare sector and is particularly known for its innovative medical technology. The company, a segment of the larger Siemens Group, specializes in diagnostic and therapeutic products and services, including medical imaging, laboratory diagnostics, and point-of-care testing. Founded in 1847 as part of Siemens AG, Siemens Healthineers was spun off as a separate entity in 2018, reflecting its focus on healthcare technology and services.
- Ticker
- €SHL
- Sector
- Health
- Primary listing
- XETRA
- Employees
- 74,300
- Headquarters
- Forchheim, Germany
- Website
- www.siemens-healthineers.com
Siemens Health Metrics
BasicAdvanced
€47B
21.18
€1.97
0.83
€1.00
2.39%
Price and volume
Market cap
€47B
Beta
0.83
52-week high
€49.78
52-week low
€32.84
Average daily volume
962K
Dividend rate
€1.00
Financial strength
Current ratio
1.162
Quick ratio
0.705
Long term debt to equity
0.6
Total debt to equity
0.783
Dividend payout ratio (TTM)
50.52%
Interest coverage (TTM)
7.96%
Profitability
EBITDA (TTM)
4,022
Gross margin (TTM)
39.02%
Net profit margin (TTM)
9.55%
Operating margin (TTM)
13.98%
Effective tax rate (TTM)
22.60%
Revenue per employee (TTM)
€310,000
Management effectiveness
Return on assets (TTM)
4.48%
Return on equity (TTM)
12.15%
Valuation
Price to earnings (TTM)
21.177
Price to revenue (TTM)
2.023
Price to book
2.44
Price to tangible book (TTM)
-9.71
Price to free cash flow (TTM)
17.977
Free cash flow yield (TTM)
5.56%
Free cash flow per share (TTM)
2.326
Dividend yield (TTM)
2.39%
Forward dividend yield
2.39%
Growth
Revenue change (TTM)
-0.92%
Earnings per share change (TTM)
2.32%
3-year revenue growth (CAGR)
2.33%
3-year earnings per share growth (CAGR)
11.62%
3-year dividend per share growth (CAGR)
1.72%
What the Analysts think about Siemens Health
Analyst ratings (Buy, Hold, Sell) for Siemens Health stock.
Analyst projections of the future price of Siemens Health stock.
Bulls say / Bears say
Equipment demand is strong: the Q3 book-to-bill ratio reached 1.27, and the company announced large US hospital partnerships. A healthy order pipeline supports future equipment sales. (Siemens Healthineers, StockAnalysis)
Newer products are gaining traction: photon-counting CT represented about 30% of CT equipment orders, while DryCool made up half of MRI units ordered. Wider adoption could support growth and strengthen the company’s competitive position. (StockAnalysis)
Precision Therapy is delivering strong growth, with Q3 comparable revenue up 9.2% and an adjusted EBIT margin of 17.5%. That performance provides a profitable growth engine beyond Diagnostics. (Siemens Healthineers)
Diagnostics remains a drag: Q3 revenue fell 5.5%, with China’s procurement policy and lower reimbursements weighing on sales, while customers move to a new laboratory platform. Management expects another mid-single-digit decline in Q4. (Reuters)
The company cut its 2026 revenue-growth forecast to 3.5–4.0% from 4.5–5.0%. Its higher EPS forecast reflects tariff refunds, while the underlying earnings outlook was unchanged, so the headline upgrade offers limited evidence of stronger operating performance. (Siemens Healthineers, StockAnalysis)
Rising supply-chain costs and currency movements are pressuring profitability. These headwinds could offset some of the benefit from stronger sales in Imaging and Precision Therapy. (StockAnalysis)
Data summarised monthly by Lightyear AI. Last updated on 25 Oct 2026.
Siemens Health Financial Performance
Revenues and expenses
Siemens Health Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing Siemens Health
AllEURUSDGBP
Fund name | Fund size | €SHL weighting |
|---|---|---|
iShares TecDAX€EXS2 | €645M | 11.76% |
iShares DivDAX€EXSB | €562M | 2.78% |
iShares Dax ESG€EXIA | €127M | 0.92% |
Xtrackers DAX£XDAX | €7.3B | 0.89% |
iShares Core DAX€EXS1 | €8.8B | 0.89% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.